Sort
50,496 grants matching “lung cancer”
Developing new immunotherapies based of CD4 T cells
$679,738Nicholas Restifo · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
TELEhealth Shared decision-making COaching for lung cancer screening in Primary care (TELESCOPE)
$679,647Anita Y Kinney · Rutgers Biomedical And Health Sciences · R01 · FY2024 · HL
Medicaid data as a complement to cohort studies for investigating cancers among older people with HIV
$679,536Corinne E. Joshu · Johns Hopkins University · R01 · FY2020 · CA
Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy
$679,295Douglas A Lauffenburger · Massachusetts Institute Of Technology · U01 · FY2021 · CA
A network approach to interrogate cellular plasticity and drug resistance in cancer
$679,232Rosemary J Akhurst · University Of California, San Francisco · R01 · FY2025 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
$679,205Derek Ronald Duckett · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
ALLOGENEIC TGF-B ANTISENSE CELL VACCINE FOR LUNG CANCER
$679,196Novarx Corporation · R44 · FY2004 · CA
ALLOGENEIC TGF-B ANTISENSE CELL VACCINE FOR LUNG CANCER
$679,195Novarx Corporation · R44 · FY2003 · CA
Developing liquid biopsy tests for malignant effusions using artificial intelligence-assisted, morphology-based isolation of tumor cells
$679,188Mark Jesus Magbanua · University Of California, San Francisco · R01 · FY2024 · CA
Immunoregulatory role of lung-resident club cell factors in lung cancer
$679,154Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Immunoregulatory role of lung-resident club cell factors in lung cancer
$679,154Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevance
$679,024Emil Schueler · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Gene-Environment Interactions in Lung Cancer
$679,009Brid Ryan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Mitochondrial deubiquitinase USP30 regulates cell metabolism-mediated miRNA biogenesis and microvascular inflammation
$678,803Yutong Zhao · Ohio State University · R01 · FY2025 · HL
Reducing Environmental Tobacco Smoke Exposure in Public Housing
$678,731Douglas Levy · Massachusetts General Hospital · R01 · FY2014 · HL
PD-L1 MODIFICATIONS IN CANCER DIAGNOSIS AND TREATMENT
$678,723Yong Li · Baylor College Of Medicine · R01 · FY2025 · CA
Risk prediction methods
$678,702Mitchell H Gail · Division Of Cancer Epidemiology And Genetics · ZIA · FY2012 · CA
POLYOMA HOST INTERACTIONS LEADING TO TUMOR DEVELOPMENT
$678,691Harvard University (Medical School) · R01 · FY2001 · CA
ETIOLOGICAL PROCESSES IN THE ONSET AND MAINTENANCE OF ADVERSE HEALTH OUTCOMES IN MALTREATED YOUTH
$678,633Christine M Heim · Pennsylvania State University, The · P50 · FY2017 · HD
EEG Biomarkers Derived from Dynamical Network Models Enable Rapid Paths to Accurate Diagnosis and Effective Treatment of Epilepsy
$678,609Sridevi V. Sarma · Johns Hopkins University · R35 · FY2024 · NS
DEFICIENT BIM EXPRESSION AS A MECHANISM OF INTRINSIC AND ACQUIRED RESISTANCE TO TARGETED THERAPIES IN EGFR-MUTANT AND ALK-POSITIVE LUNG CANCERS
$678,600The General Hospital Corporation · · FY2013 · Department of Defense
Genetic and mechanistic analysis of carbon dioxide tolerance in Cryptococcus pathogenesis
$678,567Damian J Krysan · University Of Iowa · R01 · FY2021 · AI
Center for Applied Preclinical Research (CAPR)
$678,504Terry Van Dyke · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
Role of necrosis in the evolution of highly metastatic and chemo-resistant breast cancers
$678,482Kevin Jon Cheung · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer Agents
$678,469William Douglas Figg · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA